Imperial College London
Alternate

ProfessorRichardFestenstein

Faculty of Medicine, Department of Brain Sciences

Clinical Professor of Molecular Medicine
 
 
 
//

Contact

 

+44 (0)20 3313 8310r.festenstein

 
 
//

Assistant

 

Ms Hyacinth Henry +44 (0)20 3313 3172

 
//

Location

 

London Institute of Medical Sciences, Mansfield BuildingNeptune BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Gavriel:2015,
author = {Gavriel, C and Thomik, A and Lourenco, PR and Nageshwaran, S and Athanasopoulos, S and Sylaidi, A and Festenstein, R and Faisal, A},
title = {Kinematic body sensor networks and behaviourmetrics for objective efficacy measurements in neurodegenerative disease drug trials},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AB  - In this study, we have deployed body sensor network (BSN) technology in clinical trials for monitoring and quantifying the behaviour of Friedreich's Ataxia (FRDA) patients on a longitudinal scale. Using our ETHO1 wireless BSN nodes, we captured motion time-series from patients' sleep and we extracted behavioural biomarkers that can objectively highlight the progression of the disease throughout time. The clinical scales that are currently used to capture the stage of the ataxic disease require patients to perform a series of lengthy tasks where clinicians can observe patients' performance and aggregate a score that represents the stage of the disease. Unfortunately, these scales have been shown to be inconsistent mainly due to the underlying subjective measures, they are highly dependent on the assessor's experience and they also have low sensitivity that fails to capture the slow disease progression in short periods of time. This entails lengthy clinical trials for monitoring the effects of any drugs on patients that has huge effects on the cost of medical healthcare. Using the data we collected from our clinical trials, we extracted behavioural biomarkers based on the distribution of patients' movement and stillness durations in bed during their sleep and also the intensity of their movements. Our biomarkers exhibit trends similar to patients' SARA scores, one of the standard clinical scales used for capturing the disease progression in FRDA patients. This establishes a proof of concept that BSN technology can objectively capture patients' behaviour and can be used to perform rapid efficacy of clinical measurements on the effects of drugs. Additionally, understanding the underlying effects of Friedreich's Ataxia on our motor control system can potentially enable detection of the disease at a very early stage.
AU  - Gavriel,C
AU  - Thomik,A
AU  - Lourenco,PR
AU  - Nageshwaran,S
AU  - Athanasopoulos,S
AU  - Sylaidi,A
AU  - Festenstein,R
AU  - Faisal,A
PY  - 2015///
TI  - Kinematic body sensor networks and behaviourmetrics for objective efficacy measurements in neurodegenerative disease drug trials
ER  -
Download